How COVID-19 Raised the Profile of Non-Dilutive Funding
The FreeMind Group sat down with BioPharma-Reporter reporter, Jane Byrne to discuss how the pandemic has brought non-dilutive funding to the forefront of scientific R&D. The role of non-dilutive funding is especially evident in the seemingly quick development of vaccines by Moderna, BionTech (Pfizer), and others. While the development of these vaccines appears to be at ‘warp speed’, the technology is actually based on work that has been in done since 2008 and funded through various agencies to the tune of $48 M.
These same agencies, among them the NIH, the DoD and others, are always looking for innovative ideas, and non-dilutive funding each year totals about $50B.
